Philip Siberg
Chief Executive Officer
Q3 report presentation
Philip Siberg, CEO of Senzime, presented the 2025 Q3 report on Oct 29, 9:00 CET.
Q3 2025 report presentation
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Press release
Senzime unveils the next set of innovations in neuromuscular monitoring with the launch of EMGINE Sirius
Press release
Senzime secures major TetraGraph order from leading UK NHS hospital system
Press release
Senzime to Present at Redeye and BioStock Investor Conferences
Financial info Jan - Sept 2025
Senzime Q3 2025: Strong growth and clear steps towards profitability
We continue to deliver strong growth, with sales year-to-date up 80 percent in constant currencies, corresponding to 70 percent in Swedish kronor. The growth is driven by an increasing number of hospital contracts and higher utilization among existing customers.
76
Net sales, MSEK
70
Net sales, % increase
62
Sales of disposable sensors, % increase
62.9
Gross margin before depreciation, %
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.